Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline antiplatelet effect in depressive ACS patients
NCT02463110Phase 4Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sertraline in major depressive disorder (MDD) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time dependent pattern of changes in platelet reactivity at 28 weeks. Started Jul 2015; status: terminated.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02463110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463110.